New hope for elderly esophageal cancer patients: immunotherapy without chemo
NCT ID NCT07205731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called tislelizumab in people aged 70 and older with advanced esophageal cancer who are not healthy enough for standard chemotherapy. The drug is given through an IV and aims to help patients live longer and with better quality of life. Researchers will track how many patients are alive after 6 months, as well as side effects and overall well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH Béthune et Beuvry
RECRUITINGBeuvry, France
-
CHRU Brest
RECRUITINGBrest, France
-
CHRU Lille
RECRUITINGLille, France
-
CHRU Tours
NOT_YET_RECRUITINGTours, France
-
CHU Amiens
NOT_YET_RECRUITINGAmiens, France
-
CHU Besançon
RECRUITINGBesançon, France
-
CHU Clermont-Ferrand
NOT_YET_RECRUITINGClermont-Ferrand, France
-
CHU Dijon
NOT_YET_RECRUITINGDijon, France
-
CHU Limoges
NOT_YET_RECRUITINGLimoges, France
-
CHU Nancy
RECRUITINGNancy, France
-
CHU Poitiers
RECRUITINGPoitiers, France
-
CHU Rennes
RECRUITINGRennes, France
-
CHU Rouen
RECRUITINGRouen, France
-
CHU de Reims
NOT_YET_RECRUITINGReims, France
-
Centre François Baclesse
RECRUITINGCaen, France
-
Centre Hospitalier Annecy Genevois
NOT_YET_RECRUITINGAnnecy, Epagny Metz-Tessy, 74370, France
-
Centre Hospitalier de la Côte Basque
NOT_YET_RECRUITINGBayonne, 64100, France
-
Centre Léon BERARD de Lyon
NOT_YET_RECRUITINGLyon, France
-
Centre Régional du Lutte Contre Le Cancer - Institut Godinot
NOT_YET_RECRUITINGReims, 51726, France
-
Centre hospitalier de Perpignan
NOT_YET_RECRUITINGPerpignan, France
-
Groupe Hospitalier Mutualiste
NOT_YET_RECRUITINGGrenoble, France
-
Groupe Hospitalier Rance Emeraude
RECRUITINGSt-Malo, France
-
Hôpital Européen Georges-Pompidou
RECRUITINGParis, France
-
Hôpital Saint-Louis Lariboisière
RECRUITINGParis, France
-
ICHF Centre Pierre Curie
RECRUITINGBeuvry, France
-
Institut Public de Cancérologie Strauss Europe,
NOT_YET_RECRUITINGStrasbourg, France
-
Institut de Cancérologie de l'Ouest
RECRUITINGSaint-Herblain, France
-
Institut régional du cancer Provence d'Avignon
NOT_YET_RECRUITINGAvignon, France
-
Le Groupe Hospitalier Diaconesses Croix Saint-Simon de Paris
RECRUITINGParis, France
-
Médipôle Hôpital Mutualiste
RECRUITINGVilleurbanne, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return